Exploiting pluripotency for therapeutic gain

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Human embryonic stem cells (hESCs) have been recognized as the "gold standard" for research on pluripotency and differentiation, and hold great promise for advancing our knowledge of human development, biology, disease and therapy. However, traditional techniques for generating hESCs rely on surplus IVF embryos and are incompatible with the generation of genetically diverse, patient- or disease-specific stem cells. A recent breakthrough in stem cell biology is the success of converting human somatic cells into pluripotent cells by using defined "reprogramming factors". While these repro-grammed cells have similar developmental potential as authentic hESCs, they are not derived from human embryos, and are thus termed "induced pluripotent stem cells (iPSCs)". The iPSC technology would prove useful for generation of individual cell lines from many different patients to study the nature and complexity of disease. Moreover, problems of immune rejection for future therapeutic applications would be greatly relieved by being able to generate reprogrammed cells from individual patients. Although iPSC generation is still slow, inefficient, fraught with pitfalls, and unsafe for human use, recent research has yielded exciting insights into the understanding of the technology, logic, safety, and utility of iPSCs, and has led to the use of these unusual cells for disease modeling, drug discovery and regenerative medicine, paving paths to new therapeutics.

Original languageEnglish (US)
Pages (from-to)167-173
Number of pages7
JournalPanminerva Medica
Volume52
Issue number2
StatePublished - Jun 2010

Fingerprint

Induced Pluripotent Stem Cells
Stem Cells
Embryonic Structures
Technology
Therapeutics
Regenerative Medicine
Human Development
Drug Discovery
Research
Cell Biology
Safety
Cell Line
Human Embryonic Stem Cells

Keywords

  • Human embryonic stem cells
  • Induced pluripotent stem cells
  • Regenerative medicine
  • Stem cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Exploiting pluripotency for therapeutic gain. / Deng, Wenbin.

In: Panminerva Medica, Vol. 52, No. 2, 06.2010, p. 167-173.

Research output: Contribution to journalArticle

@article{70119785edea433e814b04eacce13972,
title = "Exploiting pluripotency for therapeutic gain",
abstract = "Human embryonic stem cells (hESCs) have been recognized as the {"}gold standard{"} for research on pluripotency and differentiation, and hold great promise for advancing our knowledge of human development, biology, disease and therapy. However, traditional techniques for generating hESCs rely on surplus IVF embryos and are incompatible with the generation of genetically diverse, patient- or disease-specific stem cells. A recent breakthrough in stem cell biology is the success of converting human somatic cells into pluripotent cells by using defined {"}reprogramming factors{"}. While these repro-grammed cells have similar developmental potential as authentic hESCs, they are not derived from human embryos, and are thus termed {"}induced pluripotent stem cells (iPSCs){"}. The iPSC technology would prove useful for generation of individual cell lines from many different patients to study the nature and complexity of disease. Moreover, problems of immune rejection for future therapeutic applications would be greatly relieved by being able to generate reprogrammed cells from individual patients. Although iPSC generation is still slow, inefficient, fraught with pitfalls, and unsafe for human use, recent research has yielded exciting insights into the understanding of the technology, logic, safety, and utility of iPSCs, and has led to the use of these unusual cells for disease modeling, drug discovery and regenerative medicine, paving paths to new therapeutics.",
keywords = "Human embryonic stem cells, Induced pluripotent stem cells, Regenerative medicine, Stem cells",
author = "Wenbin Deng",
year = "2010",
month = "6",
language = "English (US)",
volume = "52",
pages = "167--173",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Exploiting pluripotency for therapeutic gain

AU - Deng, Wenbin

PY - 2010/6

Y1 - 2010/6

N2 - Human embryonic stem cells (hESCs) have been recognized as the "gold standard" for research on pluripotency and differentiation, and hold great promise for advancing our knowledge of human development, biology, disease and therapy. However, traditional techniques for generating hESCs rely on surplus IVF embryos and are incompatible with the generation of genetically diverse, patient- or disease-specific stem cells. A recent breakthrough in stem cell biology is the success of converting human somatic cells into pluripotent cells by using defined "reprogramming factors". While these repro-grammed cells have similar developmental potential as authentic hESCs, they are not derived from human embryos, and are thus termed "induced pluripotent stem cells (iPSCs)". The iPSC technology would prove useful for generation of individual cell lines from many different patients to study the nature and complexity of disease. Moreover, problems of immune rejection for future therapeutic applications would be greatly relieved by being able to generate reprogrammed cells from individual patients. Although iPSC generation is still slow, inefficient, fraught with pitfalls, and unsafe for human use, recent research has yielded exciting insights into the understanding of the technology, logic, safety, and utility of iPSCs, and has led to the use of these unusual cells for disease modeling, drug discovery and regenerative medicine, paving paths to new therapeutics.

AB - Human embryonic stem cells (hESCs) have been recognized as the "gold standard" for research on pluripotency and differentiation, and hold great promise for advancing our knowledge of human development, biology, disease and therapy. However, traditional techniques for generating hESCs rely on surplus IVF embryos and are incompatible with the generation of genetically diverse, patient- or disease-specific stem cells. A recent breakthrough in stem cell biology is the success of converting human somatic cells into pluripotent cells by using defined "reprogramming factors". While these repro-grammed cells have similar developmental potential as authentic hESCs, they are not derived from human embryos, and are thus termed "induced pluripotent stem cells (iPSCs)". The iPSC technology would prove useful for generation of individual cell lines from many different patients to study the nature and complexity of disease. Moreover, problems of immune rejection for future therapeutic applications would be greatly relieved by being able to generate reprogrammed cells from individual patients. Although iPSC generation is still slow, inefficient, fraught with pitfalls, and unsafe for human use, recent research has yielded exciting insights into the understanding of the technology, logic, safety, and utility of iPSCs, and has led to the use of these unusual cells for disease modeling, drug discovery and regenerative medicine, paving paths to new therapeutics.

KW - Human embryonic stem cells

KW - Induced pluripotent stem cells

KW - Regenerative medicine

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=77955460855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955460855&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 167

EP - 173

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 2

ER -